Mehmet Tahir Gokdemir, Gul Sahika Gokdemir, Hacer Kayhan, Cihan Gul, Beran Yokus, Ezel Tasdemir, Mukadder Baylan

The effects of rosuvastatin and pravastatin on bone metabolism in diabetic rats

Aim: In this study, the effects of rosuvastatin and pravastatin on bone metabolism were evaluated. Comparison of the positive or negative effects of two different statins on biochemical parameters related to bone metabolism in 20 mg / kg / day diabetic rats will be contribute to the enrichment of the literature on this subject. In addition, information will be obtained about whether the use of statins will be beneficial in bone metabolism disorders that may occur due to aging or diabetes in DM patients. Materials and Methods: In a diabetic rat model induced by Streptozotocin (STZ), the possible effects of Rosuvastatin and Pravastatin, both of which are hydrophilic, on biochemical parameters and histologycal examination related to bone metabolism (20 mg / kg) were examined in comparison with the control groups. Results: In the intergroup comparisons, Phosphate (P) level was lower in the Pravastatin group than the controls (P = 0.017). However, there was no difference in the P level in the Rosuvastatin group compared to the control group and the diabetes group. The calcium (Ca) level was increased in the Rosuvastatin group then the the controls (P = 0.002). However, there was no significant change in Ca level in the Pravastatin group. The vitamin D2 level of rats was similar in all groups and was not statistically significant. There was no significant difference between the groups in terms of both osteoblastic activity and bone marrow cellularity. Conclusion: In conclusion, although more extensive studies are needed, our study revealed that the serum Ca level was high in rats given rosuvastatin, and P levels were low in rats given pravastatin. But cytologically, there was no change in bone structure. Our study revealed that we should be a little more cautious about the information that statins have a positive effect on bone tissue.

PDF

___

1. Gotto AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110:3-14.
2. Tuncez A. Comparative effects of atorvastatin 80 mg versus rosuvastatin 40 mg on the neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and monocyte to HDL-cholesterol ratio in patients with acute myocardial infarction. Ann Med Res 2019;26:2045-52.
3. Hughes A, Rogers MJ, Idris AI, Crockett JC. A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function in Vitro and Ovariectomy-Induced Bone Loss In Vivo.Calcif Tissue Int 2007;81:403-13.
4. Morse LR, Coker J, Battaglino.RA. Statins And Bone Health: A MiniReview.Actual osteol 2018;14:31-5.
5. Doshi R, Kumar A, Thakkar S, et al. Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone. Am J Cardiol 2020;125:198- 204.
6. rockett JC. A Comparison between the Effects of Hydrophobic and Hydrophilic Statins on Osteoclast Function In Vitro and Ovariectomy-Induced Bone Loss In Vivo. Calcif Tissue Int 2007;81:403-13.
7. Pokhrel NK, Kim YG, Kim JY, Kim HH, Lee Y. Fluvastatin Inhibits Osteoclast Differentiation and Porphyromonas gingivalis Lipopolysaccharide-Induced Alveolar Bone Erosion in Mice.J Periodontol 2017;88:390-8.
8. Staal A, Frith JC, French MH, et al. The ability of the statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003;18:88-96
9. Monjo M, Rubert M, Ellingsen JE Lyngstadaas SP. Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells. Cell Physiol Biochem 2010;26:647- 56.
10. An T, Hao J, Sun S, et al. Efficacy of statins for osteoporosis: a systematic review and meta-analysis. Osteoporos Int 2017;28:47-57.
11. Helin-Salmivaara A, Korhonen MJ, Lehenkari P, etal. Statins and hip fracture preventionÐa population based cohort study in women. PloS one 2012;7: e48095. Doi: 10.1371/journal.pone.0048095 PMID: 23144731.
12. Morse LR, Nguyen N, Battaglino RA, et al. Wheelchair use and lipophilic statin medications may influence bone loss in chronic spinal cord injury: findings from the FRASCI-bone loss study. Osteoporos Int 2016;27:3503-11.
13. Majima T, Shimatsu A, Komatsu Y, et al. Short-term effects of pitavasta tin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern Med 2007;46:1967-73.
14. Roczniak W, Brodziak-Dopierała B, Cipora E, et al. The Content of Structural and Trace Elements in the Knee Joint Tissues.nt J Environ Res Public Health 2017;14:1441.
15. Horecka A,Hordyjewska A,Blicharski T, et al. Simvastatin Effect on Calcium and Silicon Plasma Levels in Postmenopausal Women with Osteoarthritis. Biol Trace Elem Res 2016;171:1-5
16. Ipekci SH, Baldane S, Sozen M, Kebapcilar L. Can atorvastatin calcium cause asymptomatic hypercalcemia?.Arch Turk Soc Cardiol 2014;42:662-6
17. Kawane T, Terashima S, Kurahashi I, et al. Atorvastatin enhances bone density in ovariectomized rats given 17beta-estradiol or human parathyroid hormone. Endocrine 2004;24:121-9.